Association of the ACE I/D Gene Polymorphisms with JAK2V617F-Positive Polycythemia Vera and Essential Thrombocythemia

被引:3
作者
Gorukmez, Orhan [1 ]
Sag, Sebnem Ozemri [2 ]
Gorukmez, Ozlem [2 ]
Ture, Mehmet [2 ]
Topak, Ali [2 ]
Sahinturk, Serdar [2 ]
Ozkaya, Guven [3 ]
Gulten, Tuna [2 ]
Ali, Ridvan [4 ]
Yakut, Tahsin [2 ]
机构
[1] Sevket Yilmaz Training & Res Hosp, Med Genet Unit, Bursa, Turkey
[2] Uludag Univ, Sch Med, Dept Med Genet, TR-16059 Gorukle, Bursa, Turkey
[3] Uludag Univ, Sch Med, Dept Biostat, Bursa, Turkey
[4] Uludag Univ, Sch Med, Dept Internal Med, Div Hematol, Bursa, Turkey
关键词
CONVERTING-ENZYME GENE; RENIN-ANGIOTENSIN SYSTEM; INCREASED OXIDATIVE STRESS; INSERTION/DELETION POLYMORPHISM; BONE-MARROW; MYELOPROLIFERATIVE NEOPLASMS; VENOUS THROMBOEMBOLISM; MYELOID-LEUKEMIA; GASTRIC-CANCER; RISK;
D O I
10.1089/gtmb.2014.0334
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The renin-angiotensin system contributes to cell growth, proliferation, and differentiation in the bone marrow. We investigated the role of the ACE I/D gene polymorphism in 108 polycythemia vera (PV) and essential thrombocytosis (ET) patients who were positive for the JAK2V617F mutation, with a thrombosis group (TG) of 95 patients who had a history of vascular events, but did not have a history of myeloproliferative neoplasms and compared these to a healthy control group (CG) of 72 subjects. In the patients, II genotype and I allele frequency (p=0.009, odds ratio [OR]=9.716, 95% confidence interval [CI]=1.242-76.00, p=0.004, OR=2.019, 95% CI=1.243-3.280, respectively) were found to be higher than those in the controls. The DD genotype (p=0.021, OR=0.491, 95% CI=0.268-0.899) and D allele (p=0.004, OR=0.495, 95% CI=0.305-0.805) were found to be correlated with a decreased risk of a myeloproliferative neoplasm. These findings support the hypothesis that the ACE II genotype and I allele may be related to increased risk of ET and PV. Conversely, the DD genotype and D allele may be related to decreased risk of ET and PV. The results also indicated that the ACE I/D gene polymorphism was independent of thrombosis formation.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 35 条
[1]  
Abali Huseyin, 2002, Hematology, V7, P75, DOI 10.1080/10245330290022160
[2]   Angiotensin Converting Enzyme Insertion/Deletion Gene Polymorphisms in Leukemic Hematopoiesis [J].
Akalin, Ibrahim ;
Koca, Ebru ;
Karabulut, Halil G. ;
Haznedaroglu, Ibrahim C. ;
Cetiner, Deniz ;
Hayran, Mutlu ;
Onal, Ibrahim K. ;
Ozcebe, Osman I. ;
Tukun, Ajlan .
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (01) :1-9
[3]   Enhanced expression of the local haematopoietic bone marrow renin-angiotensin system in polycythemia Rubra vera [J].
Aksu, S ;
Beyazit, Y ;
Hazneidaroglu, IC ;
Kekilli, M ;
Canpinar, H ;
Misirlioglu, M ;
Uner, A ;
Tuncer, S ;
Sayinalp, N ;
Büyükasik, Y ;
Goker, H ;
Ozcebe, OI .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2005, 33 (06) :661-667
[4]   Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML [J].
Aksu, Salih ;
Beyazit, Yavuz ;
Haznedaroglu, Ibrahim C. ;
Canpinar, Hande ;
Kekilli, Murat ;
Uner, Aysegul ;
Sayinalp, Nilguen ;
Bueyuekasik, Yahya ;
Goker, Hakan ;
Ozcebe, Osman I. .
LEUKEMIA & LYMPHOMA, 2006, 47 (05) :891-896
[5]   CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis [J].
Barbui, Tiziano ;
Finazzi, Guido ;
Falanga, Anna .
BLOOD, 2013, 122 (13) :2176-2184
[6]  
Barcelos Michelle Maccarini, 2011, Rev. Bras. Hematol. Hemoter., V33, P290, DOI 10.5581/1516-8484.20110079
[7]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[8]   Major vascular complications in essential thrombocythemia:: a study of the predictive factors in a series of 148 patients [J].
Besses, C ;
Cervantes, F ;
Pereira, A ;
Florensa, L ;
Solé, F ;
Hernández-Boluda, C ;
Woessner, S ;
Sans-Sabrafen, J ;
Rozman, C ;
Montserrat, E .
LEUKEMIA, 1999, 13 (02) :150-154
[9]  
Beyazit Y, 2007, J NATL MED ASSOC, V99, P57
[10]  
Durmus A, 2013, EUR REV MED PHARMACO, V17, P2860